- Home
- BFRI vs POAI Comparison
BFRI vs POAI Comparison
Compare BFRI & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- POAI
- Stock Information
- Founded
- BFRI 1997
- POAI 2002
- Country
- BFRI United States
- POAI United States
- Employees
- BFRI N/A
- POAI N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- BFRI Health Care
- POAI Health Care
- Exchange
- BFRI Nasdaq
- POAI Nasdaq
- Market Cap
- BFRI 7.9M
- POAI 7.8M
- IPO Year
- BFRI 2021
- POAI N/A
- Fundamental
- Price
- BFRI $0.93
- POAI $0.74
- Analyst Decision
- BFRI Strong Buy
- POAI Hold
- Analyst Count
- BFRI 1
- POAI 1
- Target Price
- BFRI $2.75
- POAI N/A
- AVG Volume (30 Days)
- BFRI 82.9K
- POAI 168.6K
- Earning Date
- BFRI 08-13-2025
- POAI 08-19-2025
- Dividend Yield
- BFRI N/A
- POAI N/A
- EPS Growth
- BFRI N/A
- POAI N/A
- EPS
- BFRI N/A
- POAI N/A
- Revenue
- BFRI $37,997,000.00
- POAI $1,729,269.00
- Revenue This Year
- BFRI $11.75
- POAI $486.27
- Revenue Next Year
- BFRI $17.09
- POAI $65.50
- P/E Ratio
- BFRI N/A
- POAI N/A
- Revenue Growth
- BFRI 14.28
- POAI 24.17
- 52 Week Low
- BFRI $0.54
- POAI $0.55
- 52 Week High
- BFRI $2.22
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- BFRI 50.53
- POAI 38.14
- Support Level
- BFRI $0.88
- POAI $0.71
- Resistance Level
- BFRI $0.96
- POAI $0.82
- Average True Range (ATR)
- BFRI 0.09
- POAI 0.04
- MACD
- BFRI -0.02
- POAI -0.00
- Stochastic Oscillator
- BFRI 16.67
- POAI 27.18
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.